Biomarkers for assessing breast cancer
US11493516B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 9, 2021 |
| Grant date | Nov 8, 2022 |
| Priority date | — |
| Expiry date | May 5, 2041 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T436/24
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to a metabolic biomarker set for use in assessing breast cancer in a mammalian subject. In particular, the invention relates to a metabolic biomarker set for screening and/or diagnosing breast cancer, the metabolic biomarker set including at least (a) one amino acid selected from glutamine, glutamate and serine, and one lipid, or (b) glutamine and glutamate. Further, the invention relates to a metabolic biomarker set for prediction of therapeutic response to breast cancer neoadjuvant chemotherapy. Moreover, the present invention relates to a method for assessing breast cancer, which includes obtaining a biological sample, preferably blood, from a mammalian subject and measuring in the biological sample the amount and/or ratios of metabolites. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess breast cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.